Detecting EGFR mutations (L858R, T790M) using allele specific multiplex sequencing: A comparison with Pyrosequencing and TruSeq

Abstract

We are presenting an evaluation of Allele Specific Multiplex Sequencing (ASMS) to detect two EGFR somatic mutations (L858R, T790M). Late stage lung cancer samples were tested for both EGFR mutations and were compared to either pyrosequencing or TruSeq. The analytical lower limit of detection (LLOD) for the ASMS-L858R assay was found to be 36 copies, and 72 copies for the ASMS-T790M assay. The forty-one FFPE samples that were tested for T790M showed 100% concordance with the respective comparative method. The forty-five FFPE samples tested previously by Truseq for L858R showed 100% concordance with ASMS. Out of the twenty L858R samples previously tested by pyrosequencing, there was 95% concordance with ASMS. Additionally, twenty-one normal blood samples were tested by ASMS were found to be negative for L858R and T790M. In conclusion, the detection of L858R and T790M by ASMS are in acceptable concordance with both pyrosequencing and TruSeq in detecting EGFR mutations from late stage lung cancer. Further, ASMS was able to detect EGFR (L858R) with 10 picograms (3 copies gDNA) of FFPE extracted DNA, and hence could be used to detect mutations from samples carrying low copy numbers.

Keywords

ASMS / EGFR / L858R / T790M / Lung cancer

References

[1] Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008 May; 21 Suppl 2: S16-22. PMid:18437168. https://doi.org/10.1038/modpathol.3801018

[2] Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associ-ated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11. PMid:15329413. https://doi.org/10.1073/pnas.0405220101

[3] Kenneth S, Thress Roz Brant T. Hedley Carr cSimon Deardend Suzanne Jenkins e Helen Brownd Tracey Hammettf Mireille Can-tarinigJ. Carl Barretta. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of lead-ing technologies to support the clinical development of AZD9291. Lung Cancer. 2015 December; 90(3): 509-515. PMid:26494259. https://doi.org/10.1016/j.lungcan.2015.10.004

[4] Sandrine Dufort, Marie-Jeanne Richard, Sylvie Lantuejoul, et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC J Exp Clin Cancer Res. 2011; 30(1): 57. PMid:21575212. https://doi.org/10.1186/1756-9966-30-57

[5] Vinayagamoorthy T, Zhang D, Ye F, Vinayagamoorthy D, Hodkinson R.Can detection of Braf p. V600E mutation be improved? Compari- son of allele specific multiplex sequencing to present tests. Journal of Solid Tumors. 2017; 7(2): 14. https://doi.org/10.5430/jst.v7n2p14

[6] Sandrine Dufort, Marie-Jeanne Richard, Sylvie Lantuejoul, et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res. 2011; 30(1): 57. https://doi.org/10.1056/NEJMoa1709684

[7] Gillian Ellison, Guanshan Zhu, Alexandros Moulis, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013; 66:79-89. PMid:23172555. https://doi.org/10.1136/jclinpath-2012-201194

[8] Martínez-Carretero C, Pascual FI, Rus A, et al. Detection of EGFR mutations in patients with non-small cell lung cancer by high res-olution melting. Comparison with other methods Clin Chem Lab Med. 2017 Oct 26; 55( 12): 1970-1978. PMid:28432840. https://doi.org/10.1515/cclm-2016-0353

[9] Hee JK, Seo YO, Wan SK, et al. Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. Oncol Lett. 2013 Jan; 5(1): 271-276. PMid:23255934. https://doi.org/10.3892/ol.2012.950

[10] Moorthy, Thurai. An algorithm to evaluate the efficacy of detect-ing somatic mutations. J Solid Tumors. 2018; 8(2): 25. https://doi.org/10.5430/jst.v8n2p25